PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide derived from melanocortin signaling research and designed as an analog of α-melanocyte-stimulating hormone (α-MSH). As a melanocortin receptor agonist, it demonstrates notable activity at central melanocortin receptor subtypes, particularly MC3R and MC4R, which are associated with neuroendocrine signaling pathways and behavioral regulation within the central nervous system.
Overview
PT-141 has attracted significant scientific interest due to its interaction with melanocortin receptor systems involved in hypothalamic and limbic network function. These receptor pathways are components of proopiomelanocortin (POMC) signaling cascades, which play roles in regulating motivated behaviors and neural responses linked to reward and drive mechanisms.
Unlike compounds that primarily exert peripheral effects, PT-141 is widely studied for its ability to engage central nervous system targets. This characteristic makes it a valuable tool for researchers exploring melanocortin-mediated mechanisms related to behavioral neuroscience, neuroendocrine regulation, and central receptor signaling.
Chemical Characteristics
PT-141 is structurally derived from the Melanotan II framework and features a modified cyclic heptapeptide sequence:
Ac-Nle-cyclo[Asp-His-D-Phe-
The peptide’s cyclic structure contributes to receptor affinity and stability, supporting its use as a selective pharmacological probe in melanocortin receptor studies. Research has demonstrated preferential agonist activity at MC3 and MC4 receptor subtypes, which are highly expressed in central neural circuits.
Research Applications
In laboratory environments, PT-141 is commonly utilized as a specialized investigative compound for examining melanocortin receptor function and signaling dynamics. Applications may include:
- Receptor binding and displacement assays
- Functional cellular reporter assays
- Calcium flux and signaling pathway studies
- Structure-activity relationship (SAR) investigations
- Molecular pharmacology and receptor mutagenesis research
Its defined receptor selectivity and structural similarity to other melanocortin ligands make it particularly useful for dissecting receptor subtype contributions to CNS processes.
Product Specifications
- Synthetic cyclic heptapeptide
- Lyophilized powder format
- Identity and purity verification provided
- Manufactured for laboratory research use
Note: This product is provided as a Lyophilized, research-grade powder and does not come in liquid form.
Disclaimer
Research Use Only Disclaimer:
Products from Flawless BioLabs are strictly for laboratory and research use by qualified professionals. They are not pharmaceuticals, dietary supplements, agricultural products, or household items, and must not be mislabeled as such. These chemicals are not intended for human or veterinary use and are exempt from Title 21, Parts 100–740 of the CFR. The information provided is educational, has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any health condition.
Intellectual Property & Patent Use Disclaimer: Flawless BioLabs provides this product solely for uses that fall under exemptions to patent infringement as permitted by applicable law, including but not limited to 35 U.S.C. § 271(e)(1) in the United States. It is the sole responsibility of the purchaser or user to ensure that their use of this product complies with all applicable intellectual property laws and legal exemptions. By purchasing this product, the buyer agrees to use it only within the scope of those exemptions and to indemnify and hold harmless Flawless BioLabs from any claims arising from its use, including any alleged intellectual property infringement.
FDA Disclaimer
The statements presented on this website have not been evaluated by the U.S. Food and Drug Administration (FDA). Products offered are not intended to diagnose, treat, cure, or prevent any disease or medical condition.
